Background: N-terminal pro-B type natriuretic peptide (NT-proBNP) is a marker of cardiac stress and is linked with silent cardiac diseases. While associations of cognitive impairment with manifest cardiovascular diseases are established, data on whether subclinical elevation of NT-proBNP levels below clinically established threshold of heart failure is related with cognitive functioning, especially mild cognitive impairment (MCI), is rare.
Objective: Aim of the present study was to investigate the cross-sectional association of NT-proBNP levels and MCI in a population-based study sample without heart failure.
Methods: We used data from the second examination of the population based Heinz-Nixdorf-Recall-Study. Subjects with overt coronary heart disease and subjects with NT-proBNP levels indicating potential heart failure (NT-proBNP≥300 pg/ml) were excluded from this analysis. Participants performed a validated brief cognitive assessment and were classified either as MCI [subtypes: amnestic-MCI (aMCI), non-amnestic-MCI (naMCI)], or cognitively-normal.
Results: We included 419 participants with MCI (63.1±7.4 y; 47% men; aMCI n = 209; naMCI n = 210) and 1,206 cognitively normal participants (62.42±7.1 y; 48% men). NT-proBNP-levels≥125 pg/ml compared to <125 pg/ml were associated with MCI in fully adjusted models (OR 1.65 (1.23;2.23) in the total sample, 1.73 (1.09;2.74) in men and 1.63(1.10;2.41) in women). For aMCI, the fully adjusted OR was 1.53 (1.04;2.25) and for naMCI, the fully adjusted OR was 1.34 (1.09; 166) in the total sample.
Conclusion: Within normal ranges and without manifest heart failure, higher NT-proBNPlevels are associated with MCI and both MCI subtypes independent of traditional cardiovascular risk factors and sociodemographic parameters.
PetersenRC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med256, 183–194.
2.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7(819), 270–279.
3.
WinbladB, PalmerK, KivipeltoM, JelicV, FratiglioniL, WahlundLO, NordbergA, BackmanL, AlbertM, AlmkvistO, AraiH, BasunH, BlennowK, de LeonM, DeCarliC, ErkinjunttiT, GiacobiniE, GraffC, HardyJ, JackC, JormA, RitchieK, van DuijnC, VisserP, PetersenRC (2004) Mild cognitive impairment–beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med256, 240–246.
4.
JurgensCY, FaulknerKM, LeeCS (2013) Phenotypic profiling of cognitive impairment risk among patients with heart failure: A literature review of the usefulness of cardiac-related variables. Eur J Cardiovasc Nurs12, 109–131.
5.
AmpaduJ, MorleyJE (2015) Heart failure and cognitive dysfunction. Int J Cardiol178, 12–23.
6.
van den HurkK, ReijmerYD, van den BergE, AlssemaM, NijpelsG, KostensePJ, StehouwerCD, PaulusWJ, KampO, DekkerJM, BiesselsGJ (2011) Heart failure and cognitive function in the general population: The Hoorn Study. Eur J Heart Fail13, 1362–1369.
7.
MaiselAS, KrishnaswamyP, NowakRM, McCordJ, HollanderJE, DucP, OmlandT, StorrowAB, AbrahamWT, WuAH, CloptonP, StegPG, WestheimA, KnudsenCW, PerezA, KazanegraR, HerrmannHC, McCulloughPA (2002) Breathing Not Properly Multinational Study Investigators: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med347, 161–167.
8.
NadirMA, RekhrajS, WeiL, LimTK, DavidsonJ, MacDonaldTM, LangCC, DowE, StruthersAD (2012) Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol60, 960–968.
9.
KaraK, MahabadiAA, GeiselMH, LehmannN, KälschH, BauerM, NeumannT, DraganoN, MoebusS, MöhlenkampS, JöckelKH, ErbelR (2014) B-type natriuretic peptide: Distribution in the general population and the association with major cardiovascular and coronary events–the Heinz Nixdorf Recall Study. Clin Res Cardiol103, 125–132.
10.
SchmermundA, MöhlenkampS, StangA, GrönemeyerD, SeibelR, HircheH, MannK, SiffertW, LauterbachK, SiegristJ, JöckelKH, ErbelR, GrönemeyerD, SeibelR, HircheH, MannK, SiffertW, LauterbachK, SiegristJ, JöckelKH, ErbelR (2002) Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: Rationale and design of the Heinz Nixdorf Recall Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am Heart J144, 212–218.
11.
JanuzziJL, van KimmenadeR, LainchburyJ, Bayes-GenisA, Ordonez-LlanosJ, Santalo-BelM, PintoYM, RichardsM (2006) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J27, 330–337.
12.
McMurrayJJ, AdamopoulosS, AnkerSD, AuricchioA, BöhmM, DicksteinK, FalkV, FilippatosG, FonsecaC, Gomez-SanchezMA, JaarsmaT, KøberL, LipGY, MaggioniAP, ParkhomenkoA, PieskeBM, PopescuBA, RønnevikPK, RuttenFH, SchwitterJ, SeferovicP, StepinskaJ, TrindadePT, VoorsAA, ZannadF, ZeiherA, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, BaxJJ, BaumgartnerH, CeconiC, DeanV, DeatonC, FagardR, Funck-BrentanoC, HasdaiD, HoesA, KirchhofP, KnuutiJ, KolhP, McDonaghT, MoulinC, PopescuBA, ReinerZ, SechtemU, SirnesPA, TenderaM, TorbickiA, VahanianA, WindeckerS, McDonaghT, SechtemU, BonetLA, AvraamidesP, Ben LaminHA, BrignoleM, CocaA, CowburnP, DargieH, ElliottP, FlachskampfFA, GuidaGF, HardmanS, IungB, MerkelyB, MuellerC, NanasJN, NielsenOW, OrnS, ParissisJT, PonikowskiP (2012) ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail14, 803–869.
13.
RobertsE, LudmanAJ, DworzynskiK, Al-MohammadA, CowieMR, McMurrayJJ, MantJ (2015) NICE Guideline Development Group for Acute Heart Failure. The diagnostic accuracy of the natriuretic peptides in heart failure: Systematic review and diagnostic meta-analysis in the acute care setting.h. BMJ350, 910.
14.
WHO (2004) The selection and use of essential medicines. World Health Organ Tech Rep Ser920, 1–127.
15.
WegeN, DlugajM, SiegristJ, DraganoN, ErbelR, JöckelKH, MoebusS, WeimarC (2011) Population-based distribution and psychometric properties of a short cognitive performance measure in the population-based Heinz Nixdorf Recall study. Neuroepidemiology37, 13–20.
ShulmanKI (2000) Clock-drawing: Is it the ideal cognitive screening test?Int J Geriatr Psychiatry15, 548–561.
19.
American Psychiatric Association (1984) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, ed. 4, American Psychiatric Association, Washington, DC.
20.
UNESCO (1997) International standard classification of education (ISCED).
21.
JöckelKH, LehmannN, JaegerBR, MoebusS, MöhlenkampS, SchmermundA, DraganoN, StangA, GrönemeyerD, SeibelR, MannK, VolbrachtL, SiegristJ, ErbelR (2009) Smoking cessation and subclinical atherosclerosis–results from the Heinz Nixdorf Recall Study. Atherosclerosis203, 221–227.
22.
MoebusS, StangA, MöhlenkampS, DraganoN, SchmermundA, SlomianyU, HoffmannB, BauerM, Broecker-PreussM, MannK, SiegristJ, ErbelR, JöckelKH, Heinz Nixdorf Recall Study Group (2009) Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort–results of the Heinz Nixdorf Recall Study. Diabetologia52, 81–89.
23.
ZuccalaG, MarzettiE, CesariM, Lo MonacoMR, AntonicaL, CocchiA, CarboninP, BernabeiR (2005) Correlates of cognitive impairment among patients with heart failure: Results of a multicenter survey. Am J Med118, 496–502.
24.
TrojanoL, Antonelli IncalziR, AcanforaD, PiconeC, MecocciP, RengoF (2003) Cognitive impairment: A key feature of congestive heart failure in the elderly. J Neurol250, 1456–1463.
25.
JeffersonAL, BeiserAS, HimaliJJ, SeshadiS, O’DonnellCJ, ManningWJ, WolfPA, AuR, BenjaminEJ (2015) Low cardiac index is associated with incident dementia and Alzheimer disease: The Framingham heart study. Circulation131, 1333–1339.
26.
AloscoML, BrickmanAM, SpitznagelMB, GarciaSL, NarkhedeA, GriffithEY, RazN, CohenR, SweetLH, ColbertLH, JosephsonR, HughesJ, RosneckJ, GunstadJ (2013) Cerebral perfusion is associated with white matter hyperintensities in older adults with heart failure. Congest Heart Fail19, E29–E34.
27.
AmpaduJ, MorleyJE (2015) Heart failure and cognitive dysfunction. Int J Cardiol178, 12–23.
28.
McAfooseJ, BauneBT (2009) Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev33, 355–366.
29.
KaraK, LehmannN, KälschH, MöhlenkampS, DykunI, Broecker-PreussM, PundtN, MoebusS, JöckelKH, ErbelR, MahabadiAA (2015) NT-proBNP is superior to BNP for predicting first cardiovascular event in the general population: The Heinz Nixdorf Recall Study. Int J Cardiol183, 155–161.
KaraK, MahabadiAA, BergMH, LehmannN, MöhlenkampS, KälschH, BauerM, MoebusS, DraganoN, JöckelKH, NeumannT, ErbelR (2014) Predicting risk of coronary events and all-cause mortality: Role of B-type natriuretic peptide above traditional risk factors and coronary artery calcium scoring in the general population – The Heinz Nixdorf Recall Study. Eur J Prev Cardiol21, 1163–1170.
33.
SabayanB, van BuchemMA, de CraenAJ, SigurdssonS, ZhangQ, HarrisTB, GudnasonV, AraiAE, LaunerLJ (2015) N-terminal pro-brain natriuretic peptide and abnormal brain aging: The AGES-Reykjavik Study. Neurology85, 813–820.
34.
HilalS, ChaiYL, IkramMK, ElangovanS, YeowTB, XinX, ChongJY, VenketasubramanianN, RichardsAM, ChongJP, LaiMK, ChenC (2015) Markers of cardiac dysfunction in cognitive impairment and dementia.e. Medicine (Baltimore)94, 297.
35.
MarksteinerJ, ImarhiagbeD, DefrancescoM, DeisenhammerEA, KemmlerG, HumpelC (2014) Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer’s disease and mild cognitive impairment: A pilot-study. Exp Gerontol50, 114–121.
36.
ZlokovicBV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci12, 723–738.
